AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX WITH NAB-PACLITAXEL PLUS GEMCITABINE FOR FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER

被引：4
|
作者：
Hollmann, S. [1 ]
Alloul, K. [2 ]
Attard, C. [1 ]
Kavan, P. [3 ]
机构：
[1] Cornerstone Res Grp, Burlington, ON, Canada
[2] Sanofi Canada, Laval, PQ, Canada
[3] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr E 715, Montreal, PQ H3T 1E2, Canada
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu164.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 0018
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [31] Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
    Kokkali, Stefania
    Tripodaki, Elli-Sophia
    Drizou, Maria
    Stefanou, Dimitra
    Magou, Elpida
    Zylis, Dimosthenis
    Kapiris, Matthaios
    Nasi, Despoina
    Georganta, Chara
    Ardavanis, Alexandros
    IN VIVO, 2018, 32 (03): : 653 - 657
  • [32] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    P. G. Corrie
    W. Qian
    B. Basu
    J. W. Valle
    S. Falk
    C. lwuji
    H. Wasan
    D. Palmer
    M. Scott-Brown
    J. Wadsley
    S. Arif
    J. Bridgewater
    D. Propper
    R. Gillmore
    A. Gopinathan
    R. Skells
    P. Bundi
    R. Brais
    K. Dalchau
    L. Bax
    A. Chhabra
    A. Machin
    A. Dayim
    K. McAdam
    S. Cummins
    L. Wall
    R. Ellis
    A. Anthoney
    J. Evans
    Y. T. Ma
    C. Isherwood
    A. Neesse
    D. Tuveson
    D. I. Jodrell
    British Journal of Cancer, 2020, 122 : 1760 - 1768
  • [33] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    Corrie, P. G.
    Qian, W.
    Basu, B.
    Valle, J. W.
    Falk, S.
    Iwuji, C.
    Wasan, H.
    Palmer, D.
    Scott-Brown, M.
    Wadsley, J.
    Arif, S.
    Bridgewater, J.
    Propper, D.
    Gillmore, R.
    Gopinathan, A.
    Skells, R.
    Bundi, P.
    Brais, R.
    Dalchau, K.
    Bax, L.
    Chhabra, A.
    Machin, A.
    Dayim, A.
    McAdam, K.
    Cummins, S.
    Wall, L.
    Ellis, R.
    Anthoney, A.
    Evans, J.
    Ma, Y. T.
    Isherwood, C.
    Neesse, A.
    Tuveson, D.
    Jodrell, D., I
    BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1760 - 1768
  • [34] Sindilimab combined with nab-paclitaxel plus gemcitabine as first-line treatment for patients with advanced pancreatic cancer.
    Zhu, Huayun
    Sun, Xiaofeng
    Pan, Xuan
    Wu, Pingping
    Chen, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients
    Demaziere, Amaury
    Mourgues, Charline
    Lambert, Celine
    Trevis, Sophie
    Bertucat, Helene
    Grange, Isabelle
    Pezet, Denis
    Sautou, Valerie
    Jary, Marine
    Gagniere, Johan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [36] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Angelica Petrillo
    Annalisa Pappalardo
    Luca Pompella
    Giuseppe Tirino
    Filomena Calabrese
    Maria Maddalena Laterza
    Marianna Caterino
    Anna Ventriglia
    Michele Orditura
    Giovanni Conzo
    Carlo Molino
    Fortunato Ciardiello
    Maria Biglietto
    Ferdinando De Vita
    Medical Oncology, 2019, 36
  • [37] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
    Borazanci, Erkut
    Von Hoff, Daniel D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 739 - 747
  • [38] Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival
    Pacheco-Barcia, V.
    France, T.
    Zogopoulos, G.
    Bouganim, N.
    Donnay, O.
    Alcindor, T.
    Mondejar Solis, R.
    Guo, K.
    Martin, E.
    Colomer, R.
    Asselah, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment
    Petrillo, Angelica
    Pappalardo, Annalisa
    Pompella, Luca
    Tirino, Giuseppe
    Calabrese, Filomena
    Laterza, Maria Maddalena
    Caterino, Marianna
    Ventriglia, Anna
    Orditura, Michele
    Conzo, Giovanni
    Molino, Carlo
    Ciardiello, Fortunato
    Biglietto, Maria
    De Vita, Ferdinando
    MEDICAL ONCOLOGY, 2019, 36 (10)
  • [40] Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine plus nab-paclitaxel
    Vivaldi, C.
    Cappelli, C.
    Donati, F.
    Fornaro, L.
    Musettini, G.
    Pasquini, G.
    Pecora, I.
    Catanese, S.
    Lencioni, M.
    Salani, F.
    Boraschi, P.
    Falcone, A.
    Vasile, E.
    ANNALS OF ONCOLOGY, 2018, 29
12345